Bibliography
- Roger SD. Biosimilars: how similar or dissimilar are they? Nephrology 2006;11:341-6
- Pisani J, Bonduelle Y. Opportunities and barriers in the biosimilar market: Evolution or revolution for generics companies? Bangalore, India: Association of Biotechnology Led Enterprises (ABLE) Available from: http://www.ableindia.org/biosimilars.pdf [Last accessed 30 January 2010]
- Ronco C. Is the advent of biosimilars affecting the practice of nephrology and the safety of patients? Contrib Nephrol 2008;161:261-70
- Schellekens H. Biopharmaceuticals and biosimilars, unraveling the complexity. EJHP Pract 2006;5:13
- Nowicki M. Basic facts about biosimilars. Kidney Blood Press Res 2007;30:267-72
- Mikhail A. Biosimilars in clinical practice. Kidney Blood Press Res 2007;30(Suppl 1):18-22
- Bohlega S, Al-Shammri A, Al Sharoqi I, Biosimilars: opinion of an expert panel in the Middle East. Curr Med Res Opin 2008;24(10):2897-903
- Frequently asked questions about generic medicines. Brussels, Belgium: European Generic Medicines Association, 2007. Available from: www.egagenerics.com/FAQ-generics.htm [Last accessed 30 January 2010]
- Questions and answers on generic medicines. EMEA document. EMEA/393905/2006. London, UK: European Medicines Agency, 2007. Available from: www.emea.europa.eu/pdfs/human/pcwp/39390506en.pdf [Last accessed 30 January 2010]
- Questions and answers on biosimilar medicines (similar biological medicinal products). EMEA document EMEA/74562/2006. London, UK: European Medicines Agency, 2007. Available from: www.emea.europa.eu/pdfs/human/pcwp/7456206en.pdf [Last accessed 30 January 2010]
- Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v13-16
- EBE-EFPIA Position Paper. Inapplicability of automatic substitution rules to biotechnology products, including biosimilar medicinal products: Recommendations for addressing unique safety concerns. Available from: http://www.ebe-biopharma.org/documents/biosimilars/biosimilars_substitutionpos.pdf [Last Accessed 10 December 2009]
- Casadevall N, Rossert J. Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol 2005;18:381-7
- Lim LC. Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure. Hematology 2005;10:255-9
- Schellekens H. Follow-on biologics: challenges of the ‘next generation’. Nephrol Dial Transplant 2005;20(Suppl 4):iv31-36
- Declerck PJ. Biotherapeutics in the era of biosimilars: what really matters is patient safety. Drug Saf 2007;30(12):1087-92
- Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant 2006;21(Suppl 5):v5-8
- Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-62
- Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004;22:1383-91
- Crommelin DJ, Storm G, Verrijk R, Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int J Pharm 2003;266:3-16
- Wenzel RG. Biosimilars: illustration of scientific issues in two examples. Am J Health Syst Pharm 2008;65(14 Suppl 6):S9-15
- Robertson JS. Changes in biological source material. Biologicals 2006;34:61-3
- Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002;24:1720-40
- Belsey MJ, Harris LM, Das RR, Biosimilars: initial excitement gives way to reality. Nat Rev 2006;5:535-6
- Roger SD, Mikhail A. Biosimilars: opportunity or cause for concern? J Pharm Pharm Sci 2007;10(3):405-10
- Schellekens H. When biotech proteins go off-patent. Trends Biotechnol 2004;22(8):406-10
- Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006;21(Suppl 5):v9-12
- Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol 2004;251(Suppl 2):II4-9
- Chirino AJ, Ary ML, Marshall SA. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 2004;9:82-90
- Schellekens H. How similar do “biosimilars” need to be? Nat Biotech 2004;22(11):1357-9
- Guideline on similar biological medicinal products. London, UK: European Medicines Agency, 2005. Available from: http://www.ema.europa.eu/pdfs/human/biosimilar/043704en.pdf [Last Accessed 30 January 2010]
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa.eu/pdfs/human/biosimilar/4934805en.pdf [Last accessed 30 January 2010]
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, UK: European Medicines Agency, 2006. Available from: http://www.ema.europa.eu/pdfs/human/biosimilar/4283205en.pdf [Last accessed 30 January 2010]
- Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008;19:411-9
- Joshi SR. Biosimilar Insulins: are they really ‘similar’? JAPI 2009;57(Suppl):338-41
- Joung J, Robertson JS, Griffiths E, WHO informal consultation on regulatory evaluation of therapeutic biological medicinal products held at WHO Headquarters, Geneva, 19-20 April 2007. Biologicals 2008;36:269-76
- Central Drug Standards Control Organization. Biological Guidance for Industry. New Delhi, India: Central Drug Standards Control Organization, Ministry of Health & Family Welfare, Government of India. 2009. Available from: http://cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf [Last accessed 30 January 2010]